Category: Federal Forum Posters
Purpose: Obesity is a major contributor to type 2 diabetes and cardiovascular disease. Weight reduction has been shown to improve the body’s insulin sensitivity and glycemic control. The primary objective is 12 month weight reduction outcomes comparing empagliflozin to liraglutide
in Veterans Integrated Service Network (VISN) 15 veterans who have type 2 diabetes and are not on insulin at the time of inclusion. The secondary objectives are to compare the two agents in hemoglobin A1c (HbA1c) reduction and cardiovascular outcomes.
Methods: This is a retrospective, cohort, multisite study that has been submitted to the Institutional Review Board for approval. The national Corporate Data Warehouse (CDW) database within the Veterans Affairs Informatics and Computing Infrastructure (VINCI) will be queried to identify cases matching inclusion criteria: at least 18 years old with type 2 diabetes, HbA1c of 7 percent or greater, a body mass index (BMI) of at least 27 kilograms per meters squared, and an estimated glomerular filtration rate (eGFR) of at least 45 milliliters per minute. Veterans will be included if they were started on liraglutide or empagliflozin prior to November 1, 2017 and outcomes will be followed for 12 months. The primary and secondary outcome events will be analyzed using linear regression analysis. Baseline characteristics will be evaluated using chi squared analysis for categorical data and the t test for continuous data. Two tailed p values of less than 0.05 will be considered to indicate statistically significant differences. All calculations will be computed using statistical software provided within the VINCI workspace.
Results: not applicable
Conclusion: not applicable
Natalie Koury– PGY1 Pharmacy Resident, VA Eastern Kansas Healthcare System, Lawrence, KS